RVLPQ (RVL Pharmaceuticals) Long-Term Debt: $0.00 Mil (As of Jun. 2023)


RVLPQ RVL Pharmaceuticals PLC RVLPQ
12 GF Score
Price $0.00
View Full Analysis

What is RVL Pharmaceuticals Long-Term Debt?

RVL Pharmaceuticals RVLPQ -90.00% 12 Long-Term Debt is $0.00 Mil as of Jun. 2023. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

RVL Pharmaceuticals's Long-Term Debt for the quarter that ended in Jun. 2023 was $0.00 Mil.

RVL Pharmaceuticals's quarterly Long-Term Debt declined from Dec. 2022 ($55.50 Mil) to Mar. 2023 ($53.04 Mil) and declined from Mar. 2023 ($53.04 Mil) to Jun. 2023 ($0.00 Mil).

RVL Pharmaceuticals's annual Long-Term Debt declined from Dec. 2020 ($219.53 Mil) to Dec. 2021 ($43.80 Mil) but then increased from Dec. 2021 ($43.80 Mil) to Dec. 2022 ($55.50 Mil).

RVL Pharmaceuticals  (OTCPK:RVLPQ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

RVL Pharmaceuticals Long-Term Debt Related Terms

RVL Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals Long-Term Debt Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Debt
Get a 7-Day Free Trial 266.80 267.95 219.53 43.80 55.50

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.90 55.90 55.50 53.04 0.00
RVLPQ
12GF Score
RVL Pharmaceuticals PLC RVLPQ
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
RVL Pharmaceuticals (RVLPQ) has a Long-Term Debt of $0.00 Mil as of Jun. 2023.
Is RVL Pharmaceuticals' Long-Term Debt too high?
RVL Pharmaceuticals' current Long-Term Debt is $0.00 Mil. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' Long-Term Debt compare to SNPX and THAR?
RVL Pharmaceuticals' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. RVL Pharmaceuticals's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current Long-Term Debt is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score

Get the complete analysis for RVLPQ

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price